Macrogenics (MGNX) Research & Development (2012 - 2026)

Macrogenics (MGNX) has reported Research & Development for 15 consecutive years, with $35.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 11.9% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $142.4 million (down 16.63% YoY), while the FY2025 annual figure was $147.2 million, down 16.94% from the prior year.
• Research & Development improved to $35.0 million in Q1 2026 per MGNX's latest filing, from $34.0 million in the prior quarter.
• Across five years, Research & Development topped out at $61.4 million in Q1 2022 and bottomed at $30.1 million in Q3 2023.
• Historically, Research & Development has averaged $43.1 million across 5 years, with a median of $43.2 million in 2023.
• Annual changes were most pronounced in 2023 — Research & Development tumbled 37.48% — and 2024, when it jumped 34.56%.
• Macrogenics' Research & Development stood at $45.7 million in 2022, then climbed by 3.72% to $47.4 million in 2023, then dropped by 17.87% to $38.9 million in 2024, then slipped by 12.64% to $34.0 million in 2025, then climbed by 2.94% to $35.0 million in 2026.
• Business Quant data shows MGNX's Research & Development at $35.0 million in Q1 2026, $34.0 million in Q4 2025, and $32.7 million in Q3 2025.